Background
==========

Muscle-invasive bladder cancer incidence increases with age and peaks in the octogenarians \[[@B1],[@B2]\]. Even though radical cystectomy (RC) is the gold standard for this disease \[[@B3]\], it is underused and possibly inappropriately denied, because the majority of these patients are either unfit for surgery or have considerable comorbidities. This selection bias might preclude a potential effective management in the older patients \[[@B4]\]. The above argument is further strengthened by a recent report concluding that bladder-sparing protocols in octogenarians with \> pT2 disease and American Society of Anesthesiologists (ASA) score 3--4 has a very bad prognosis \[[@B5]\].

Increased surgical experience and improvements in surgical techniques are constantly expanding the indications for aggressive treatment. This fact provided the rationale for our study, which attempted to investigate the feasibility of RC in these high-risk patients and establish a potential benefit on cancer-specific survival in the long term.

Methods
=======

We reviewed the files of 81 patients, 61 men and 20 women, with a mean age of 79.2 years (SD = 3.7 years) (range 75--95 years). All patients, after providing informed consent, underwent RC and pelvic lymphadenectomy from 2000 through 2009. Ethical approval was not required due to the retrospective nature of the study, as stated by our institutions scientific committee. The clinical and demographic characteristics of the patients are shown in Table [1](#T1){ref-type="table"}. The indications for RC were muscle invasive disease, non muscle invasive disease refractory to intravesical chemotherapy and/or immunotherapy and palliation treatment for uncontrolled haemorrhage (in 11 out of 81 patients). No patient had distant metastasis at the time of the operation. No patient received neo-adjuvant chemotherapy or radiotherapy, while 12 (14.8%) and 3 patients (3.7%) received adjuvant chemotherapy and external beam radiotherapy, respectively.

###### 

Demographic and clinical characteristics of the study group

                                           **N**      **%**
  ------------------------------------- ------------ -------
  **Gender**                                             
     Men                                     61       75.3
     Women                                   20       24.7
  **Age (years) , mean (SD)**            79.2(3.7)   
  **Age (years)\***                                      
     \<77                                    23       28.4
  77-80                                      31       38.3
     \>80                                    27       33.3
  **BMI, mean (SD)**                     25.5(3.2)   
  **Urinary diversion**                                  
     Ileal conduit                           39       48.1
     S-pouch                                 5         6.2
     Cutaneous ureterostomy                  37       45.7
  **pT (TNM system)**                                    
     pTis                                    12       14.8
     pT1 to pT2b                             28       34.6
     pT3a to pT3b                            29       35.8
     pT4a to pT4b                            12       14.8
  **Nodes (TNM system)**                                 
     0                                       60       74.1
     1-2                                     21       25.9
  **Hospital stay (days), mean (SD)**    13.0 (7.3)  
  **Charlson score**                                     
     ≤6                                      69       85.2
     \>6                                     12       14.8

\*categorized according to tertiles.

BMI: Body mass index.

SD: Standard deviation.

Perioperative complications were defined as complications occurring within the first 10 postoperative days. 90-day morbidity and mortality were also recorded. The Martin criteria for standardized reporting of complications were used \[[@B6]\] (Table [2](#T2){ref-type="table"}). The complications were classified according to the modified Clavien classification system \[[@B7]\] (Table [3](#T3){ref-type="table"}). Follow-up of the patients was performed by scheduled hospital visits and telephone interviews.

###### 

Martin criteria for standardized complication reporting

  **Criteria**                                       **Requirement**
  -------------------------------------------------- -----------------------------------------------------------------------------
  Method of accruing data defined                    Prospective or retrospective accrual of data are indicated.
  Duration of follow-up indicated                    Report clarifies the time period of postoperative accrual
                                                     of complications such as 30 days or same hospitalization.
  Outpatient information included                    Study indicates that complications first identified following
                                                     discharge are included in the analysis.
  Definitions of complications provided              Article defines at least one complication with specific inclusion criteria.
  Mortality rate and causes of death listed          The number of patients who died in the postoperative period of study
                                                     are recorded together with cause of death.
  Morbidity rate and total complications indicated   The number of patients with any complication and the total number
                                                     of complications are recorded.
  Procedure-specific complications included           
  Severity grade utilized                            Any grading system designed to clarify severity of complications
                                                     including "major and minor" is reported.
  Length-of-stay data                                Median or mean length of stay indicated in the study.
  Risk factors included in the analysis              Evidence of risk stratification and method used indicated by study.

###### 

Clavien classification of perioperative and 90-day morbidity and mortality

  **CLAVIEN grade**                                                                                                                                                                                                                                                                                                                                                                                     **N**     **%**                                            **N**     **%**
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- -------- ---------- -------------------------------------- -------- ----------
                                                                                                                                                                                                                                                                                                                                                              **Perioperative morbidity (0-10d)**       **35**   **43.2**  **90-day morbidity**                    **30**    **37**
  **1**                                                                                                                                                                                                                                                                                                                                                                                                 **11**   **13.6**                                          **15**   **18.6**
  Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics, electrolytes, and physiotherapy. This grade also includes wound infections opened at the bedside.   Hyperemesis                                 1        1.2     Pneumonia                                 2        2.4
                                                                                                                                                                                                                                                                                                                                                              Fever                                       7        8.4     Psoas abscess                             1        1.2
                                                                                                                                                                                                                                                                                                                                                              Ileus                                       1        1.2     Wound infection                           11       13.6
                                                                                                                                                                                                                                                                                                                                                              Pneumonia                                   1        1.2     Lympocele                                 1        1.2
                                                                                                                                                                                                                                                                                                                                                              Urine leakage                               1        1.2                                                          
  **2**                                                                                                                                                                                                                                                                                                                                                                                                 **22**   **27.2**                                          **4**    **4.8**
  Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included.                                                                                                                                                                                      Blood transfusion                           21       25.9    Wound dehiscense                          1        1.2
                                                                                                                                                                                                                                                                                                                                                              UTI                                         1        1.2     UTI                                       3        3.6
  **3**                                                                                                                                                                                                                                                                                                                                                                                                 **1**    **1.2**                                           **6**    **7.2**
  Requiring surgical, endoscopic or radiological intervention                                                                                                                                                                                                                                                                                                                                                                                                                   
  **3a**                                                                                                                                                                                                                                                                                                                                                      **-**                                     **-**     **0**                                            **2**    **2.4**
  Intervention not under general anesthesia                                                                                                                                                                                                                                                                                                                   \-                                          \-        0      Cardiac arrythmia-pacemaker               1        1.2
                                                                                                                                                                                                                                                                                                                                                                                                                           Obstructive nephropathy                   1        1.2
  **3b**                                                                                                                                                                                                                                                                                                                                                                                                **1**    **1.2**                                           **4**    **4.8**
  Intervention under general anesthesia                                                                                                                                                                                                                                                                                                                       Rectal injury, re-operation, colostomy      1        1.2     Evisceration, re-operation                1        1.2
                                                                                                                                                                                                                                                                                                                                                                                                                           Stricture ileus, re-operation             2        2.4
                                                                                                                                                                                                                                                                                                                                                                                                                           Incisional hernia                         1        1.2
  **4**                                                                                                                                                                                                                                                                                                                                                                                                 **1**    **1.2**                                           **2**    **2.4**
  Life-threatening complication (including CNS complications) requiring IC/ICU management                                                                                                                                                                                                                                                                     Sepsis                                      1        1.2     Myocardial Infarction                     1        1.2
                                                                                                                                                                                                                                                                                                                                                                                                                           Sepsis                                    1        1.2
  **5**                                                                                                                                                                                                                                                                                                                                                       **-**                                     **-**     **0**                                            **3**    **3.7**
  Death of a patient                                                                                                                                                                                                                                                                                                                                                                                                       **Death**                               **3**    **3.7**
                                                                                                                                                                                                                                                                                                                                                                                                                           *30-day* (sepsis, pneumonia)              2        2.4
                                                                                                                                                                                                                                                                                                                                                                                                                           *60-day* (evisceration, re-operation      1        1.2
                                                                                                                                                                                                                                                                                                                                                                                                                           *90-day*                                  0         0

Statistical analysis
--------------------

Quantitative variables are expressed as mean (±SD) or as median values (interquartile range). Qualitative variables are expressed as absolute and relative frequencies. Life table analyses were used to calculate cumulative survival rate (standard errors) for specific time intervals. The prognostic value of each variable was first assessed by univariate Cox regression analysis. Variables that showed significant association with the outcome were included in the multivariate Cox proportional-hazard model in a stepwise method, in order to determine the independent predictors for morbidity and oncological outcome. The assumption of proportional hazards was evaluated by testing for interaction with a continuous time variable. Kaplan -- Meier survival estimates for soft and hard events were graphed over the follow-up period. All reported p values are two-tailed. Statistical significance was set at p \< 0.05 and analyses were conducted using the SPSS statistical software (version 17.0).

Results
=======

The mean follow-up period was 2.6 ± 1.6 years with median equal to 2.4 years (interquartile range from 1.2 to 3.9 years). During the follow-up period, the perioperative morbidity rate was 43.2% (N = 35), 90-day morbidity rate was 35.8% (N = 29), the perioperative and overall mortality rates were 3.7% and 21.0%, respectively, while 6 patients had metastasis (7.4%). In salvage RC, perioperative morbidity rate was 45.4%, 90-day morbidity rate reached 36.4%, while perioperative mortality was 9%. Positive nodes were found in 25.9% of the patients. The mean length of hospitalization was 13.0 ± 7.3 days and 14.8% of the patients had an age-adjusted Charlson comorbidity index (ACCI) more than six. Table [4](#T4){ref-type="table"} presents the results of univariate analysis for the association of study parameters with perioperative morbidity. Perioperative morbidity rate was not significantly different when adjusted to the clinical and demographic characteristics of the patients. Univariate Cox regression analysis for 90-day morbidity (Table [5](#T5){ref-type="table"}) revealed that increased age, increased body mass index (BMI), hospital stay and ACCI more than six, were associated with greater hazard for 90-day morbidity. When multiple Cox regression analysis with stepwise-forward approach was applied (Table [6](#T6){ref-type="table"}), it was found that age, BMI, hospital stay and ACCI were independently associated with morbidity. Specifically, for one day increase in hospital stay, the morbidity hazard increases by 6%, while for one unit increase in BMI, the morbidity hazard increases by 18%. Furthermore, patients aged 77 to 80 years and those aged more than 80 years had greater morbidity hazard compared to those aged less than 77 years with adjusted hazard ratios equal to 4.92 and 5.86, respectively. Additionally, subjects with ACCI more than six had 2.51 times greater morbidity hazard compared to those with ACCI equal or less than six. Kaplan Meier morbidity estimations according to ACCI are presented in Figure [1](#F1){ref-type="fig"}.

###### 

Demographic and clinical characteristics of the study group associated with perioperative morbidity

                                  **Perioperative morbidity (10 days)**   **Px² test**                     
  ------------------------------ --------------------------------------- -------------- ----------- ------ ---------
  **Gender**                                                                                                    
     Male                                          36                         59.0          25       41.0    0.752
     Female                                        11                         55.0           9       45.0       
  **Age (years) , mean (SD)**                   79.3(4.0)                  78.9(3.2)     0.650\*\*         
  **Age (years)**                                                                                               
     \<77                                          14                         60.9           9       39.1    0.895
     77-80                                         17                         54.8          14       45.2       
     \>80                                          16                         59.3          11       40.7       
  **BMI, mean (SD)**                            25.6(2.9)                  25.5(3.7)     0.873\*\*         
  **Urinary diversion**                                                                                         
     Ileal conduit                                 22                         56.4          17       43.6   0.724\*
     S-pouch                                        4                         80.0           1       20.0       
     Cutaneous ureterostomy                        21                         56.8          16       43.2       
  **pT (TNM system)**                                                                                           
     pTis                                           3                         25.0           9       75.0    0.070
     pT1 to pT2b                                   17                         60.7          11       39.3       
     pT3a to pT3b                                  18                         62.1          11       37.9       
     pT4a to pT4b                                   9                         75.0           3       25.0       
  **Nodes (TNM system)**                                                                                        
     0                                             34                         56.7          26       43.3    0.675
     1-2                                           13                         61.9           8       38.1       
  **Hospital stay, mean (SD)**                  13.7(8.4)                  12.1(5.4)     0.334\*\*         
  **Charlson score**                                                                                            
     ≤6                                            39                         56.5          30       43.5    0.511
     \>6                                            8                         66.7           4       33.3       

\*Indicates reference category.

\*\*Hazard ratio cannot be calculated because of no distribution.

###### 

Univariate and multiple Cox proportional hazards models for the prediction of 90-day morbidity

                                       **Crude**                   **Adjusted**          
  ------------------------------ --------------------- ------- --------------------- -------
  **Gender**                                                                             
     Male                               1.00\*                                           
     Female                       0.98 (0.42 - 2.28)    0.955                            
  **Age (years), mean ± SD**      1.08 (0.99 - 1.17)    0.079                            
  **Age (years)**                                                                        
     \<77                               1.00\*                        1.00\*             
     77-80                        4.12 (1.18 - 14.33)   0.026   4.92 (1.35 - 17.95)   0.016
     \>80                         4.04 (1.14 - 14.31)   0.031   5.86 (1.47 - 23.42)   0.012
  **BMI, mean ± SD**              1.15 (1.04 - 1.27)    0.008   1.18 (1.04 - 1.34)    0.011
  **Urinary diversion**                                                                  
     Ileal conduit                      1.00\*                                           
     S-pouch                             \*\*                                            
     Cutaneous ureterostomy       1.18 (0.57 - 2.44)    0.658                            
  **pT (TNM system)**                                                                    
     pTis                               1.00\*                                           
     pT1 to pT2b                  0.51 (0.18 - 1.42)    0.197                            
     pT3a to pT3b                 0.62 (0.23 - 1.72)    0.362                            
     pT4a to pT4b                   0.56 (0.16 - 2)     0.377                            
  **Nodes (TNM system)**                                                                 
     0                                  1.00\*                                           
     1-2                           1.2 (0.53 - 2.7)     0.665                            
  **Hospital stay, mean ± SD**    1.05 (1.02 - 1.09)    0.002   1.06 (1.02 - 1.09)    0.002
  **Charlson score**                                                                     
     ≤6                                 1.00\*                        1.00\*             
     \>6                           2.43 (1.03 - 5.7)    0.042   2.51 (1.06 - 5.94)    0.037

‡Hazard Ratio (95% Confidence Interval).

\*Indicates reference category.

\*\*Hazard ratio cannot be calculated because of no distribution.

###### 

Univariate and multiple Cox proportional hazards models for the prediction of death/metastasis

                                       **Crude**                   **Adjusted**          
  ------------------------------ --------------------- ------- --------------------- -------
  **Gender**                                                                             
     Male                               1.00\*                                           
     Female                        0.41 (0.12 - 1.4)    0.155                            
  **Age (years), mean ± SD**        1 (0.89 - 1.13)     0.976                            
  **Age (years)**                                                                        
     \<77                               1.00\*                                           
     77-80                        1.57 (0.57 - 4.34)    0.382                            
     \>80                         1.06 (0.36 - 3.17)    0.910                            
  **BMI, mean ± SD**               0.96 (0.84 - 1.1)    0.563                            
  **Urinary diversion**                                                                  
     Ileal conduit                      1.00\*          0.997                            
     S-pouch                             \*\*                                            
     Cutaneous ureterostomy       1.03 (0.45 - 2.36)    0.944                            
  **pT (TNM system)**                                                                    
     pTis                               1.00\*                        1.00\*             
     pT1 to pT2b                  3.11 (0.37 - 25.88)   0.293   2.87 (0.35 - 23.9)    0.329
     pT3a to pT3b                  5.5 (0.7 - 43.04)    0.105   5.99 (0.76 - 46.95)   0.088
     pT4a to pT4b                 9.11 (1.09 - 75.81)   0.041   9.19 (1.10 - 76.58)   0.040
  **Nodes (TNM system)**                                                                 
     0                                  1.00\*                        1.00\*             
     1-2                          2.52 (1.10 -- 5.75)   0.028    2.4 (1.05 - 5.49)    0.039
  **Hospital stay. mean ± SD**    0.99 (0.93 - 1.06)    0.777                            

![Kaplan-Meier curves for 90-day morbidity stratified by age-adjusted Charlson comorbidity index (p = 0.037).](1471-2318-12-18-1){#F1}

The cumulative mortality / metastasis-free rates for one, two, three and five years were 88.7% \[Standard Error (SE) = 3.6%\], 77.5% (SE = 4.8%), 70.4% (SE = 5.5%) and 62.3% (SE = 7.3%), respectively. Both univariate and multiple analysis concerning death or metastasis (Table [5](#T5){ref-type="table"}) revealed that tumour stage and nodes were prognostic predictors for oncological outcome. Specifically, as resulted from multiple analysis, patients with tumour stage pT4a to pT4b had 9.19 times greater hazard for death or metastasis compared to those with in situ tumours. Moreover, patients with one or two positive nodes had 2.4 times greater hazard for death or metastasis. Kaplan Meier estimates for death or metastasis according to tumour stage and nodes are presented in Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}, respectively.

![Kaplan-Meier curves for event-free probability stratified by nodal status. (p = 0.039).](1471-2318-12-18-2){#F2}

![**Kaplan-Meier curves for event-free probability stratified by tumour stage.** (pT1-pT2b: p = 0.329, pT3: p = 0.08, pT4: p = 0.04).](1471-2318-12-18-3){#F3}

Discussion
==========

Octogenarians are per se, a high-risk group, due to their comorbidities. Using the age-adjusted Charlson comorbidity index, for each decade over the age of 40 years, one point is added to the total score, a fact that reflects the significance of age in the performance status of a patient \[[@B8]\]. Koppie et al recently suggested the association between ACCI and the clinical and oncological outcome after a RC \[[@B9]\]. Other authors also reported that postoperative morbidity is higher in patients with higher ASA score and more than 2 comorbidities \[[@B10]\]. The same conclusion was reached by a collaborative review, which however, stated that age alone does not preclude RC in the elderly \[[@B11]\].

Our results of perioperative mortality and 90-day morbidity are comparable to those of the above mentioned reviews, which range between 0-11% and as high as 64% \[[@B11]\], respectively, support the notion of an aggressive treatment offered to octogenarians. The 90-day instead of the 30-day or the 60-day morbidity was selected because it is already established as a more potent and realistic description tool of the postoperative risks of the RC morbidity, as several reports are suggesting \[[@B11],[@B12]\]. The 90-day morbidity along with the use of the Clavien classification system, give a distinct advantage in our study in terms of complication reporting quality \[[@B11]-[@B13]\].

The incidence of wound complications was surprisingly high in our series (11%) and it could be attributed to poor healing capacity and poor patient hygiene. In order to avoid this kind of complication, we now routinely use tension sutures along with Nylon sutures or clips for wound closure at the end of the operation, which are removed approximately one month later.

The complication rates did not vary between salvage and primary RC. The main difference was that perioperative mortality was significantly higher in the salvage RC (9% vs. 3.7%), which was somewhat expected, due to the nature of the disease and the performance status of the patient at the time of the operation. The above observation is in accordance to other authors \[[@B14],[@B15]\]. Furthermore, obesity and longer hospital stay have been identified as risk factors for higher postoperative morbidity.

The selected type of urinary diversion does not seem to alter the morbidity/mortality outcome, as shown in other studies as well \[[@B11],[@B16]\]. It is however important to notice, that high-volume centers, performing \> 50 RC's per year should be involved in these cases, because the surgical experience in these centers is more advanced and is associated with improved postoperative outcomes, including decreased mortality, shorter length of hospital stay and lower rehospitalization rates \[[@B11],[@B17]\].

Cancer-specific survival is another major concern when the decision to perform RC in an octogenarian should be taken, as the reported results are rather controversial. Two retrospective studies, reviewing a total of approximately 1120 patients have reported unfavourable oncological outcomes in elderly patients \[[@B18],[@B19]\]. In the first study, the 5-year was 28.1%, while in the second the 3-year and 7-year cancer-specific survival rates were between 70% and 55.2%, respectively. On the other hand, Chamie et al and Hollenbeck et al provided some evidence that RC has some benefit in the elderly, when compared to watchful waiting, or radiotherapy and chemotherapy \[[@B4],[@B20]\]. Chamie and colleaques also stated that pelvic lymphadenectomy should be performed in order for RC to show any survival advantage in the octogenarians \[[@B20]\]. Based on our results, we advocate RC and lymphadenectomy in the elderly patients, since the 5-year survival rate in our series was significantly high (62.3%) and tumour stage and node status were prognostic predictors for the oncological outcome. Clinical tumour stage and grade remain the best predictors of cancer specific survival \[[@B21]\]. Therefore, it is imperative for the RC candidates to undergo a meticulous clinical and imaging examination.

Conclusions
===========

Age should not hamper RC, particularly when it takes place in specialized, high-volume centers. The reported complication rates of this particular group of patients, especially when standardized with validated methodologies, are acceptable. Strict selection of non obese patients, with non metastatic disease and an ACCI less than six, may result in a better postoperative outcome.
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